Last edition
News about "Rare Diseases"
New patient-derived xenograft study demonstrates strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, paving the way for expanded clinical evaluation in Phase 1/2a trials.
Rare Diseases | 09/07/2026 | By News Bureau
Vyome Secures China Patent for Besifloxacin Topical Gel in Inflammatory Acne Treatment
Vyome Holdings has secured a Chinese patent for its proprietary besifloxacin topical gel programme, strengthening intellectual property protection for inflammatory acne treatment and expanding future commercial opportunities in one of the world's largest dermatology markets.
Rare Diseases | 04/07/2026 | By News Bureau
Sanofi Names Paulo Fontoura to Lead Global R&D Operations
Sanofi has appointed Paulo Fontoura as Global Head of Research and Development (R&D). Based in Paris, he will join the Executive Committee and report directly to CEO Belén Garijo.
Rare Diseases | 23/06/2026 | By News Bureau | 134
Chiesi Presents New Metreleptin Data and Patient Care Insights at ENDO 2026
Chiesi Global Rare Diseases presented five new studies at ENDO 2026, highlighting advances in metreleptin therapy for lipodystrophy, potential combination treatments, and the urgent need to address mental health challenges and care gaps among patients with the rare disorder.
Rare Diseases | 20/06/2026 | By News Bureau
ImmunoForge Unveils LMT15 Platform to Transform CNS Drug Delivery
The clinical-stage biotech firm ImmunoForge is advancing its next-generation blood-brain barrier shuttle technology, combining enhanced brain permeability with long-acting formulations to accelerate therapies for CNS and rare diseases.
Rare Diseases | 24/04/2026 | By News Bureau
RION Forms INTENT Biologics to Develop Clinical Exosome-Based Therapies
With the launch of INTENT Biologics, RION targets global impact in inflammation care; Suneet Varma named CEO to lead the charge.
Rare Diseases | 11/09/2025 | By Dineshwori | 558
PLI Scheme Brings Down Rare Disease Treatment Costs from Crores to Lakhs: Pharma Secretary
The Production Linked Incentive (PLI) Scheme for pharmaceuticals has significantly reduced the cost of treating rare diseases in India, bringing expenses down from crores to just a few lakhs, said Amit Agrawal, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Rare Diseases | 22/08/2025 | By Dineshwori | 184
Lupin Announces Appointment of Claus Jepsen as President-Global Specialty
Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases.
Rare Diseases | 22/10/2024 | By Aishwarya | 454
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy